Pharma Focus Asia

Thermo Fisher Opens New Commercial Manufacturing Site in Plainville, USA


Thermo Fisher Scientific Inc., has recently announced its plans to expand its facility for increasing capacity of viral vector development and manufacturing services located at Plainville, Mass, USA.


The project with an investment of $180 million, doubles the size of the company's commercial viral vector capacity to support the rising demand of development and manufacturing of gene therapies and vaccines.

The project is expected to provide around 200 job opportunities.The state-of-the-art facility will have digital connectivity and capabilities to drive operational efficiencies, high quality, data visibility and advanced operator training.

The new site comprises of laboratory and production sites, with warehousing and office space also on-site. The site attracts diverse workforce of scientists, quality control specialists and production teams.

This expansion accelerates the cell and gene therapy innovation, thus giving hope to more patients everywhere.

Construction of the facility is expected to be completed by 2022.


NameThermo Fisher Scientific Inc
Budget$180 million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference